A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies

2006314 citationsJournal Article

Authors

Intravenous administration of LBH589 was well tolerated at doses <11.5 mg/m(2) with consistent transient antileukemic and biological effects.

Good health and well-being

Published in: Clinical Cancer Research

Volume 12, Issue 15, pp. 4628-4635

Field-Weighted Citation Impact: 10.46